A method for in vitro perfusion separation and purification of primary mouse hepatocytes
By employing a unidirectional perfusion pathway and a fluorescence-quenched peptide substrate reaction in the in vitro perfusion separation and purification method of primary mouse hepatocytes, and dynamically adjusting the enzyme perfusion time, the problem of insufficient adaptability of fixed perfusion time endpoints was solved, thereby improving the accuracy of enzyme activity detection and cell purification effect.
Patent Information
- Application Number
- CN202611498741.6
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2026-09-24
- Publication Date
- 2026-11-17
AI Technical Summary
In existing methods for the in vitro perfusion separation and purification of primary mouse hepatocytes, the fixed perfusion time endpoint is not well-suited, and there is a problem of false endpoints in the bypass, which leads to inaccurate enzyme activity detection and affects the cell purification effect.
A unidirectional perfusion path was adopted. By inputting flushing fluid and enzyme perfusion fluid, influent control samples and effluent samples were obtained respectively. Enzyme activity penetration ratio and relative conductance were determined by fluorescence quenching peptide substrate reaction. Combined with tissue status indicators, the enzyme perfusion time was dynamically adjusted to ensure that the enzyme activity signal was consistent with the tissue response.
It effectively reduces interference from enzyme activity detection, minimizes individual differences, improves the accuracy of enzyme perfusion and cell purification, and ensures that the purification path corresponds to the actual quality status.
Smart Images

Figure CN123107908A_ABST
Abstract
Description
Technical Field
[0001] This invention belongs to the field of in vitro organ perfusion technology, and relates to a method for in vitro perfusion separation and purification of mouse primary hepatocytes. Background Technology
[0002] Primary mouse hepatocytes are commonly used for drug metabolism, toxicology evaluation, liver disease mechanisms, and cell function studies. Current isolation procedures for primary mouse hepatocytes typically involve first washing the liver vascular network with a calcium-free or chelating buffer solution, followed by perfusion with an enzyme solution containing collagenase to loosen the extracellular matrix, and then releasing, filtering, centrifuging, or density separation.
[0003] However, collagenase or complex tissue dissociation enzyme preparations exhibit batch-to-batch activity variations, and enzyme solution temperature, storage time, and tubing residence time also affect their actual activity. Simply stopping enzyme perfusion at a fixed time cannot reflect the penetration and action status of the current batch of enzyme preparation in the current isolated liver; relying solely on color, swelling degree, or feel is easily influenced by operator experience and lighting conditions. If the cannula is loose, the non-target vessel ends are open, the liver capsule is damaged, or a low-resistance channel is formed locally, the enzyme solution can bypass the tissue to be digested and flow out rapidly, forming a high outflow enzyme activity signal similar to a normal completed state. Therefore, detecting high enzyme activity in the outflow does not necessarily indicate that the tissue has been fully digested, and a single enzyme activity endpoint may therefore produce a false endpoint.
[0004] Furthermore, fluorescence resonance energy transfer (FRET) substrates can rapidly produce fluorescence changes by breaking the quenching between the donor and quencher groups through enzymatic cleavage, but the enzyme profiles of different peptide substrates are not the same. Substrates suitable for matrix metalloproteinases, oligopeptides, or a certain type of collagenase cannot be directly equated to response substrates for bacterial collagenase or complex enzyme preparations used for tissue dissociation without verification; turbidity, proteins, endogenous proteases, and residual chelated components in the effluent can also cause matrix effects.
[0005] Therefore, there is a need for an ex vivo perfusion separation method that can obtain relative enzyme activity information within the enzyme perfusion decision time, reduce individual differences by utilizing the hydraulic baseline of the same ex vivo liver, and trigger different process actions when the enzyme activity signal and tissue response are inconsistent. Summary of the Invention
[0006] The purpose of this invention is to provide a method for the in vitro perfusion separation and purification of primary mouse hepatocytes, in order to solve the problems of insufficient adaptability of fixed perfusion time endpoints and false endpoints of bypass in existing in vitro perfusion separation and purification methods.
[0007] To achieve the above objectives, the present invention adopts the following technical solution: This application provides a method for the in vitro perfusion separation and purification of primary mouse hepatocytes, the method comprising: S01: A one-way perfusion pathway is established in isolated mouse liver, wherein the path of the one-way perfusion pathway is from the inlet blood vessel segment through the intrahepatic vascular network to the outlet blood vessel segment. S02: Flushing fluid is introduced along the unidirectional irrigation path to obtain the flushing baseline conductance G0; S03: Input the enzyme perfusion solution along the one-way perfusion path, and obtain an inlet control sample and an outlet sample before and after the enzyme perfusion solution enters the one-way perfusion path, respectively. S04: The influent control sample and the effluent sample are reacted with paired fluorescent quenching peptide substrates under the same detection conditions to obtain the enzyme activity breakthrough ratio R. E ; S05: During enzyme perfusion, the current flow conductance G and tissue status index T of the enzyme perfusion fluid perfusion of the unidirectional perfusion pathway are obtained; the tissue status index T includes at least one of the following: color, surface morphology and compliance of isolated mouse liver. S06: Based on the enzyme activity penetration ratio R E Relative conductance R G The tissue state index T determines whether to stop the infusion of the enzyme perfusion solution; the relative conductance R G The current flow rate G / flushing baseline flow rate G0; S07: After stopping the infusion of the enzyme perfusion solution, add the stop solution, separate and purify to obtain a cell suspension containing primary hepatocytes.
[0008] The present invention has the following beneficial effects: (1) In this application, the influent control sample and the effluent sample obtained according to the transmission delay come from the same batch of enzyme perfusion fluid. The two form a ratio under the same detection conditions to reduce the interference of input activity changes on process judgment.
[0009] (2) In this application, the flushing baseline flow rate and the current flow rate are both taken from the same ex vivo liver and are defined in the same way, so that subsequent hydraulic changes are expressed relative to the initial state of the liver itself, thereby reducing the influence introduced by differences in liver weight, vascular status and tubing connection when only the absolute flow rate across the liver is used.
[0010] (3) In this application, enzyme activity penetration ratio, relative conductivity and tissue status correspond to different information sources. The three indicators are used together to determine whether to stop the input of enzyme perfusion fluid. When the enzyme activity index is inconsistent with the hydraulic or tissue response, the process does not directly output completion, but switches to pathway inspection, correction and resampling, so that the abnormal state corresponds to different treatment actions as the normal completion state.
[0011] (4) After stopping the infusion of enzyme perfusion solution, obtain the release solution containing mouse liver through the stop solution. After filtering the release solution, first obtain a quality evaluation sample, and then select the minimum necessary intensity of enrichment or supplemental purification according to the quality gate of the same batch of filtrate, so that the purification path corresponds to the actual quality state of the filtrate. Whether the above effect has achieved the predetermined level shall be based on the calibration and verification results under the corresponding conditions. Attached Figure Description
[0012] Figure 1 A schematic flowchart illustrating the in vitro perfusion separation and purification method for primary mouse hepatocytes provided in this application embodiment; Figure 2 A schematic diagram of the structure of the component for establishing a unidirectional irrigation path provided in an embodiment of this application; Figure 3 A schematic diagram of the structure of the component for detecting paired sampling provided in an embodiment of this application; Figure 4 This is a flowchart illustrating the process of determining whether to terminate the input of enzyme perfusion fluid, as provided in an embodiment of this application. Detailed Implementation
[0013] Terminology Explanation: Isolated mouse liver: Liver that has been separated from the living organism; the source, acquisition and use of isolated liver should comply with applicable animal ethics and laboratory management requirements.
[0014] Transmission delay: The time required for the enzyme perfusion solution to travel from the inlet sampling port through the isolated mouse liver to the outlet sampling port.
[0015] Paired samples: influent control sample and effluent sample obtained according to transmission delay.
[0016] Completion range: The allowable range determined by correlating process indicators with subsequent cell yield, viability, purity, adhesion, or functional indicators through preliminary experiments.
[0017] Main perfusion direction: During both the flushing and enzyme perfusion phases, the perfusion fluid enters through the inlet segment of the vessel, flows through the intrahepatic vascular network, and exits through the outlet channel. A brief transition period due to dead volume in the tubing is permissible when switching reservoirs, but samples from this transition period are not used to calculate the enzyme activity penetration ratio or current conductance.
[0018] Under identical testing conditions: the same settings are used for the influent sample, effluent sample, and corresponding quality control in terms of sample volume, substrate batch and final concentration, final reaction volume, reaction buffer system, temperature, mixing order, time from sample addition to reading, and fluorescence reading rules. If simultaneous reading is not possible, readings are performed in a pre-validated staggered order, ensuring that the influent and effluent samples experience the same time shift.
[0019] Valid paired samples: The time correspondence between the influent and effluent samples meets the transmission delay requirements, both are within the confirmed linear reaction window, the blank, parallel reaction, and spiked recovery meet the pre-defined acceptance conditions, and the total time from influent sampling to status output does not exceed the maximum decision delay. If any of these conditions are not met, the paired samples are only used for abnormal recording and not for output perfusion completion.
[0020] Completion range: This is not a fixed value applicable across devices, enzyme preparations, and mouse sources, but rather a range determined by candidate endpoint experiments within a defined applicable stratification. E R G The determination range is obtained by correlating T with the cell yield, viability, hepatocyte purity, adherence status, or target function after termination. For applicable stratification, at least the following should be recorded: mouse source and liver weight range, enzyme type and batch, perfusion fluid system, temperature, driving method, sampling cycle, substrate, and readout settings. If the range exceeds the validated stratification range, the original completion interval should not be directly used.
[0021] Safety boundaries: Pre-determined limits on pressure, flow rate, capsule state, and maximum enzyme exposure time during the calibration phase, based on the tubing, cannulation, liver weight range, and drive method used. Safety boundaries are used for protection logic that takes precedence over completion decisions; if any safety condition is exceeded, even if R... E R G If T is in the completion interval, first reduce or stop the perfusion and perform anomaly checks.
[0022] Quality gate: A purification triage rule formed by evaluating cell viability and tissue debris or non-hepatic parenchymal cell load using predetermined methods on the mixed filtrate and comparing the evaluation results with the corresponding acceptance conditions. The indicators, sampling methods, acceptance conditions, and purification pathways used in the quality gate are bound to the same version number and are not replaced by unverified subjective observations.
[0023] In the embodiments of this application, different mouse sources, liver quality, enzyme preparations, and perfusion devices will affect the applicable conditions. During implementation, the temperature, flow rate, pressure, enzyme concentration, sampling cycle, and judgment interval should be calibrated based on the materials and equipment used. The technical solution of this invention will be further explained and illustrated below through specific embodiments.
[0024] Please refer to the attached document. Figure 1 This application provides a method for the in vitro perfusion separation and purification of primary mouse hepatocytes, the method comprising: S01: A unidirectional perfusion pathway is established in isolated mouse livers, wherein the path of the unidirectional perfusion pathway is from the inlet blood vessel segment through the intrahepatic vascular network to the outlet blood vessel segment.
[0025] Mouse livers that had been isolated, with a largely intact liver capsule and a connection between the portal vein and hepatic vein were selected as isolated mouse livers. Liver livers with obvious tears, extensive capsule damage, or inability to establish a continuous pathway between the portal vein and hepatic vein were excluded before perfusion, and the reasons were recorded.
[0026] In this embodiment, the components for establishing a unidirectional perfusion path include: a flushing fluid storage unit 120, an enzyme perfusion fluid storage unit 130, a perfusion drive unit 140, and an outlet collection unit 112, as shown in the attached figure. Figure 2 As shown. The flushing fluid storage unit 120 and the enzyme perfusion fluid storage unit 130 are respectively connected to the input end of the perfusion drive unit 140, so as to complete the switching between flushing fluid and enzyme perfusion fluid while maintaining the main perfusion direction.
[0027] The perfusion drive unit 140 is used to supply flushing fluid or enzyme perfusion fluid to the isolated mouse liver 110. Therefore, the output end of the perfusion drive unit 140 is connected to the portal vein segment of the isolated mouse liver 110 and closes the severed end of the blood vessel located outside the target pathway that would cause a significant bypass. A liquid inlet sampling port 151 is provided between the perfusion drive unit 140 and the isolated mouse liver 110 to facilitate the collection of flushing fluid or enzyme perfusion fluid before it enters the isolated mouse liver 110.
[0028] In this embodiment, the perfusion drive unit 140 may be a constant liquid column, a peristaltic pump, a syringe pump, or other components capable of providing a measurable driving pressure differential. Regardless of the driving method used, a safety boundary should be set to prevent significant capsule rupture, tubing detachment, or backflow, and this safety boundary should be determined jointly by the tubing, liver quality, and preliminary experiments.
[0029] The fluid outlet channel of the isolated mouse liver 110 is connected to the fluid collection section 112, that is, the hepatic vein is connected to the fluid collection section 112, so that the fluid collection section 112 can collect the flushing fluid or enzyme perfusion fluid after infusion. In order to facilitate the collection of fluid after infusion, a fluid sampling port 161 is provided between the hepatic vein of the isolated mouse liver 110 and the fluid collection section 112.
[0030] The flow conductivity detection unit 170 is a functional component that measures the outflow volume or flow rate per unit time, as well as the pressure information at the inlet and outlet ends. The pressure measurement points of the flow conductivity detection unit 170 are respectively set at an upstream position near the inlet blood vessel connection and at a position that can characterize the reference pressure on the outlet side. The outflow volume or flow rate is obtained within the same time window as the pressure difference. Thus, the flow conductivity detection unit 170 obtains the outflow volume per unit time corresponding to the outflow collection unit 112 and the driving pressure difference applied by the perfusion drive unit 140 to the inlet and outlet ends of the isolated mouse liver 110.
[0031] When the fluid flowing through the isolated mouse liver 110 is directly discharged into the outflow collection section 112, which is connected to the atmosphere, the pressure at the outflow surface can be used as the outflow side reference, and the height difference between the inflow measurement point and the outflow surface can be corrected. When the isolated mouse liver 110 and the outflow collection section 112 are connected by a closed tubing, the pressures on the inflow and outflow sides are measured separately. Before measuring liver conductance, the baseline pressure drop of the tubing is obtained using a pre-filled tubing not connected to the liver to identify any abnormal contributions of the cannulation or the tubing itself to the measurement.
[0032] Before connecting the above-mentioned components to the isolated mouse liver 110, it is pre-filled with rinsing fluid or enzyme perfusion fluid to remove visible air bubbles and prevent them from affecting the results. The process of establishing a unidirectional perfusion pathway using the above-mentioned components is as follows: the severed end of the blood vessel connected to the target pathway and preventing the fluid from passing through the main intrahepatic vascular network is sealed, and the sealing element does not enter the intrahepatic cavity. The portal vein segment of the isolated mouse liver 110 is connected to the perfusion drive unit 140, and the hepatic vein is connected to the outflow collection unit 112; at the same time, the perfusion drive unit 140 is connected to the rinsing fluid reservoir 120 and the enzyme perfusion fluid reservoir 130, respectively, and the outflow collection unit 112 is connected to the flow conduction detection unit 170. Thus, a unidirectional perfusion pathway is established from the portal vein segment through the intrahepatic vascular network with the outflow end being the hepatic vein.
[0033] After establishing the unidirectional perfusion pathway, flushing fluid is first introduced into the pathway to facilitate low-drive pathway acceptance. Acceptance criteria include at least the following: no continuous leakage at any connection point in the unidirectional perfusion pathway; continuous fluid output; no visible jetting at the sealed ends; no progressive local bulging of the liver capsule; and no visible air bubbles continuing to move towards the liver within the pathway. If these acceptance criteria are met, the unidirectional perfusion pathway is established. If these criteria are not met, the pathway is re-fixed, sealed, or vented to re-establish the unidirectional perfusion pathway.
[0034] S02: Flushing fluid is introduced along the unidirectional irrigation path to obtain the flushing baseline conductance G0.
[0035] The flushing solution is introduced along the unidirectional perfusion path, and the blood in the unidirectional perfusion path is drained while observing whether the outflow is continuous. In this embodiment, the flushing solution is a buffer system suitable for liver perfusion and free of collagenase. If the flushing solution contains EDTA (Ethylenediaminetetraacetic Acid), EGTA (Ethylene glycol bis(2-aminoethylether)-N,N,N',N'-tetraacetic acid), or other chelating components, sufficient replacement with enzyme perfusion solution should be performed before switching to enzyme perfusion solution to avoid residual components in the flushing solution inhibiting calcium-dependent enzyme reactions.
[0036] Once the flushing fluid is stably supplied, obtain the outflow volume Q0 and driving pressure difference per unit time. Based on the outflow volume Q0 per unit time and the driving pressure difference. The baseline conductance G0 of the flushing is calculated, i.e. .
[0037] When the irrigation drive unit 140 is driven by a constant liquid column, if the pressure difference of the constant liquid column is stable within the allowable range, the flow rate can also be characterized by the liquid column height correction. This serves as the baseline flow guide for flushing. This flow rate characterization... It is linked to the batch number of isolated mouse livers and is not directly replaced by the absolute flow rate of different livers.
[0038] During the flushing phase, the stable flushing window is determined by multiple consecutive measurement time windows. Within this window, the flushing fluid flows continuously, Q0 and ΔP0 do not exhibit continuous unidirectional drift, the liver capsule state does not change progressively, and the results of adjacent windows are within the pre-defined stability allowable range. At this point, representative values within the stable window are read as Q0 and ΔP0, and each original window value is saved, without replacing them with a single instantaneous reading.
[0039] S03: The enzyme perfusion solution is introduced along the unidirectional perfusion path, and an inlet control sample and an outlet sample are obtained before and after the enzyme perfusion solution enters the unidirectional perfusion path, respectively.
[0040] Close the pipeline between the flushing fluid reservoir 120 and the perfusion drive unit 140, and open the pipeline between the enzyme perfusion fluid reservoir 130 and the perfusion drive unit 140, so that the liquid in the unidirectional perfusion path is switched from flushing fluid to enzyme perfusion fluid, and the input path of enzyme perfusion fluid is the same as that of flushing fluid.
[0041] After switching the flushing solution to the enzyme perfusion solution, first eliminate the transition volume created by the dead volume in the inlet tubing. After the transition is complete, the effective tubing volume and flow rate can be calculated beforehand and verified using liquid tracer characteristics, ionic strength, conductivity, color marking, or other methods that do not affect the enzyme reaction. Inlet and outlet samples during the transition phase are not included in the endpoint determination.
[0042] When the liquid in the unidirectional perfusion path is entirely enzyme perfusion fluid and the flow is stable, the enzyme perfusion fluid before entering the isolated mouse liver 110 is obtained through the inlet sampling port 151 as an inlet control sample. Simultaneously, based on a pre-measured transmission delay τ, fluid is sampled at the outlet sampling port 161 at the outlet end of the isolated mouse liver 110, serving as the outlet sample corresponding to the inlet control sample according to the transmission delay τ. Thus, the inlet control sample and the outlet sample are sampled in pairs.
[0043] In this embodiment, the enzyme perfusion solution is a complex tissue dissociation enzyme preparation comprising collagenase and neutral protease suitable for dissociating the extracellular matrix of liver tissue cells, and may also contain calcium ions and buffer components. The specific enzyme preparation, concentration, and temperature are determined based on actual batch activity and preliminary experiments.
[0044] In this embodiment, the transmission delay τ can be determined using a tracer front that does not significantly react with isolated mouse liver 110, a known tubing volume and measured flow rate, or other validated methods. When the flow rate of the enzyme perfusion fluid changes significantly, τ needs to be re-estimated or updated according to validated correction rules.
[0045] When using a tracer method to determine τ, the tubing delay from the inlet sampling port 151 to the cannula inlet is checked in a tubing not connected to the liver being tested. Then, a short-term tracer change that will not be significantly adsorbed, reacted to, or have its conductance altered by liver tissue is input into the established unidirectional perfusion pathway. Simultaneously, the same tracer feature is recorded at both the inlet sampling port 151 and the outlet sampling port 161. The difference between the time points of the same tracer feature at the two locations is taken as the transmission delay under the corresponding driving condition. This feature time point can be selected as the time point when the rising edge reaches the same normalization ratio, the peak time point, or the pre-validated time point of maximum cross-correlation, but the same algorithm is used for the same batch.
[0046] When the tracer response exhibits significant broadening and cannot be represented by a single time point, an effluent sampling window is set according to the time distribution of the effluent response, ensuring its center matches the main effluent response corresponding to the influent sample, and the start and end times of the window are recorded. Pathways where stable pairings cannot be obtained are not used for R-based sampling. E The endpoint determination.
[0047] When estimating τ using the volumetric method, the effective displacement volume Veff from the inlet sampling position to the outlet sampling position is first determined through a tracer experiment. Then, the transmission delay τ is calculated based on the measured flow rate for the corresponding time period. The formula is τ = Veff / Q. When only the pipeline geometric volume is used to replace Veff, it is necessary to prove that intrahepatic retention and diffusion will not cause the pairing error to exceed the preset allowable range.
[0048] For each pair sampling, record the start and end times of influent sampling, the start and end times of effluent sampling, the corresponding time period Q, and the version of τ used. When the measured flow rate Q changes more than the pre-defined update conditions relative to the flow rate when τ is determined, or when the passage is re-fixed, vented, cleared, or closed, τ is re-determined or corrected before pair sampling resumes.
[0049] S04: The influent control sample and the effluent sample are reacted with paired fluorescent quenching peptide substrates under the same detection conditions to obtain the enzyme activity breakthrough ratio R. E .
[0050] Pairs of equal-volume influent and effluent samples were reacted with paired fluorescent quenching peptide substrates under identical conditions. The initial fluorescence change slope after blank correction was used as the basis for the reaction. and The enzyme activity breakthrough ratio is calculated as follows: If the output enzyme activity penetration ratio is inversely related to enzyme activity, it should first be converted to a positive activity index using the same calibration function before calculating the ratio. E It is used to characterize the relative detectable enzyme activity of the same batch of enzyme solution after passing through an isolated liver, and is not equivalent to the total amount of collagen that has been hydrolyzed in the tissue.
[0051] In this embodiment, the component for detecting paired sampling includes an inlet reaction station 181, an outlet reaction station 182, a fluorescence reading unit 183, a quality control reaction station 184, and a status determination unit 190. Figure 3 As shown.
[0052] Specifically, reaction sites 181 (inlet reaction) and 182 (outlet reaction) are for the inlet control sample and the outlet sample, respectively. Both reaction sites use the same batch of fluorescence-quenched peptide substrate and an equal volume of reaction buffer, maintaining the same temperature, mixing order, and reading time. Reaction site 184 is for quality control and can be set as one or more of reagent blank, sample blank, and spiked recovery. A sample blank without substrate is set for each inlet control sample and each outlet sample; a reagent blank without sample is also set. For matrix comparability verification, spiked recovery reactions are set for both the inlet and outlet matrices. All reactions can be performed simultaneously in different wells of the same porous carrier or in multiple reaction vessels maintaining a uniform time sequence.
[0053] The inlet reaction station 181, outlet reaction station 182, and quality control reaction station 184 are set up to form independent reaction spaces, which can avoid sample cross-contamination and fluorescence crosstalk. Sampling, dilution, buffer replacement, and sample addition use a pre-fixed sequence; if dilution or buffer replacement is required, the inlet and outlet samples use the same multiple, the same material, and the same processing time.
[0054] The fluorescence reading unit 183 reads the fluorescence signals of the inlet reaction site 181, the outlet reaction site 182, and the quality control reaction site 184 according to a unified reading rule, and provides the detection results and detection validity information to the status determination unit 190. The fluorescence reading unit 183 acquires readings at least two time points within a pre-confirmed initial linear window. For each inlet and outlet sample, a sample blank without substrate is set to correct for autofluorescence and time drift; a reagent blank can be further used to correct for spontaneous substrate changes. The corrected slopes are denoted as follows: and In this embodiment, the detection results and detection validity information provided by the fluorescence reading unit 183 to the state determination unit 190 include not only vin and vout, but also blank correction results, parallel reaction dispersion, spiked recovery results, linear window compliance, saturation status, and time from sampling to output.
[0055] The state determination unit 190 receives the fluorescence detection results from the fluorescence reading unit 183, the conductivity results from the conductivity detection unit 170, and tissue state indicators, and calculates and uses R based on these results. E Then, one can choose to stop enzyme perfusion, continue perfusion, or check the pathway and resample.
[0056] In this embodiment, the initial fluorescence change slope is obtained by fitting all valid readings within a linear window, rather than representing it solely by the difference between any two readings. The starting point of the linear window avoids the stage where sample mixing is not yet complete, and the ending point precedes the stage where there is significant substrate depletion, signal saturation, or a deviation from linearity in the reaction rate. The fitting method, minimum number of readings, and fitting acceptance criteria are fixed in the same detection version.
[0057] Before entering the state determination unit 190, the detection validity of the fluorescence reading unit 183 should be checked for paired samples. For the influent sample, the time slope of the corresponding influent sample blank is first subtracted from the time slope of the reaction containing the fluorescence-quenching peptide substrate, and the reagent blank is subtracted according to the detection rules to obtain vin; the effluent sample is obtained in the same way to obtain vout. If the sample is below the detection limit, any reaction signal reaches saturation, the variation of parallel reactions exceeds the preset allowable range, the spike recovery of the influent and effluent samples does not meet the preset comparability conditions, or the time from sampling to result output exceeds the maximum decision delay, the fluorescence reading unit 183 provides invalid detection information to the status determination unit 190, and the status determination unit 190 does not use the sample output perfusion completion signal.
[0058] When the fluorescence reading unit 183 provides invalid detection information, the status determination unit 190 retains the most recent valid status but does not add a new completion judgment based on it, and prioritizes determining whether it is still within the safe perfusion window. If continued is permitted, the enzyme solution input is paused or reduced, identifiable sampling or detection problems are corrected, and resampling is performed; if a valid result cannot be obtained within the maximum decision delay or the longest enzyme exposure time, the process is terminated safely.
[0059] After resampling, new paired samples are formed using a new timestamp and τ version, without cross-pairing previous invalid influent samples with subsequent effluent samples. The reason for invalidity, corrective actions taken, number of retests, and final processing results are written into the batch record.
[0060] R E Numerical interpretation is limited by the substrate, instrument, reaction conditions, sample preparation, and enzyme preparation stratification. If any of these conditions are changed in a way that alters the concentration-slope relationship or matrix effect, the original permissible detection range should first be confirmed using quality control samples and representative influent and effluent matrices to ensure its applicability.
[0061] In this embodiment, the fluorescence-quenching peptide substrate is matched with the enzyme preparation in the enzyme perfusion solution. Before using the fluorescence-quenching peptide substrate, it is necessary to determine the response of the fluorescence-quenching peptide substrate to the enzyme preparation, the linear range in the influent and effluent matrices, the time required to complete one detection, and the intra-batch repeatability, and to determine the lower limit of detection, linear range, upper limit of saturation, allowable range of parallel reactions, and spiked recovery conditions. After changing the enzyme preparation type or substrate batch, the same items are re-verified.
[0062] In this embodiment, substrate matching evaluation is required when screening fluorescence-quenching peptide substrates. Specifically, substrate matching evaluation includes the following information: examining the concentration-response relationship of the actual enzyme preparation, the linear reading range in the influent and effluent matrices, the time from sampling to result output, background under enzyme-free and enzyme-inactivated conditions, spiked recovery, and cross-response with other protein hydrolytic activities. The applicability of a fluorescence-quenching peptide substrate for screening is determined by its detection results in the actual enzyme preparation and corresponding sample matrix; known substrates of other proteases cannot replace the above matching evaluation.
[0063] In this embodiment of the application, when the enzyme preparation in the enzyme perfusion fluid is bacterial collagenase, the fluorescence quenching peptide substrate includes the FRET peptide, which forms a collagen-like triple helix conformation: Gly-mep-Flp-(Gly-Pro-Hyp)4-Gly-Lys(Mca)-Thr-Gly-Pro-Leu-Gly-Pro-Pro-Gly-Lys(Dnp)-Ser-(Gly-Pro-Hyp)4-NH2, wherein the fluorescence... The donor group Mca and the quencher group Dnp are located on both sides of the bacterial collagenase cleavage site. The triple helix region provides a recognition environment that is close to the collagen-like conformation. mep is (2S,4R)-4-methylproline, Flp is (2S,4R)-4-fluoroproline, and Hyp is 4-hydroxy-L-proline. Mca is a 7-methoxycoumarin-4-acetyl fluorescent group attached to the lysine side chain, and Dnp is a 2,4-dinitrophenyl quencher group attached to the lysine side chain.
[0064] When using FRET peptides in practice, it is necessary to verify their response and the impact on non-collagenase protein hydrolysis activity according to the batch of enzyme preparation used, reaction buffer system, detection temperature, and allowable detection time. The complete structure, purity, dissolution medium, storage conditions, and batch number should be recorded. FRET peptides should only be used to calculate R under the same enzyme preparation batch and under conditions verified by matrix spiked recovery. E When the source of supply, batch of synthesis, labeling location, or linkage method of the fluorescence quenching peptide substrate is changed, it is considered a substrate version change and a matching check is performed again.
[0065] In the embodiments of this application, when the enzyme perfusion fluid is rapidly detected using a FRET peptide containing the AGGPLGPPGPGG sequence and with fluorescent donors and quenchers set at appropriate positions, the sequence can be dissociated by tissues to respond to different protein hydrolysis activities in the enzyme preparation. Therefore, the reading is defined as the total enzymatic activity of the current complex enzyme preparation, rather than the collagenase specific activity.
[0066] When the enzyme preparation in the enzyme perfusion solution is a complex enzyme preparation containing multiple proteolytic activities, if the fluorescence-quenched peptide substrate responds to both collagenase and neutral protease, the detection result is limited to the total detectable proteolytic activity of the complex enzyme preparation under given substrate and reaction conditions. In this case, the completion interval is only applicable to enzyme preparations of the same composition category and those that have been verified, and the obtained R is not considered. E This is explained as the specific penetration rate of collagenase.
[0067] Before using fluorescence-quenched peptide substrates to calculate enzyme activity penetration ratio, pre-validation was performed using the enzyme preparation used in the enzyme perfusion solution, an enzyme-free control, and a control containing at least one non-collagenase proteolytic activity that may be present in the enzyme preparation. The fluorescence-quenched peptide substrate was only used for calculation if the response of the fluorescence-quenched peptide substrate to the enzyme preparation was higher than that to the non-collagenase proteolytic activity control, an initial linear response range existed in both the influent and effluent matrixes, and the detection results were output within the preset enzyme perfusion decision window. .
[0068] To evaluate the contribution of endogenous proteases in the effluent, substrate background response was measured using effluent matrix without exogenous enzymes but processed through a similar liver pathway, effluent matrix with inactivated exogenous enzymes, or a validated equivalent control. If this response is sufficient to alter R... E For the relevant decision interval, more selective substrate, sample preprocessing, or background subtraction rules are used; if a stable rule cannot be formed, the substrate is not used for online endpoint determination.
[0069] Comparability of spiked recoveries is determined by comparing the recovery results of the influent and effluent matrices at the same spiking level. The spiking amount should be within the established linear range and should not saturate the reaction. If the influent and effluent recoveries are not comparable, the matrix effect should not be offset by a simple ratio; instead, the sample pair should be deemed invalid and reprocessed or resampled.
[0070] The reaction buffer system should ensure that the influent and effluent samples are tested under the same final volume, ionic strength, pH, and calcium ion conditions. If residual chelated components in the wash solution or the concentration of proteins in the effluent cause matrix effects, validated proportional dilution, rapid buffer replacement, or matrix matching methods can be used, but the same rules must be applied to both influent and effluent samples.
[0071] In this embodiment, parallel reactions are used to identify errors in sample addition, mixing, and reading. When parallel results exceed a preset range of variation, the original readings are retained and the entire pair of samples is marked as invalid. A completed status is not output after selectively deleting a particular parallel well, unless pre-defined outlier rules have been verified during calibration.
[0072] S05: During enzyme perfusion, obtain the current flow conductance G and tissue status index T of the enzyme perfusion fluid perfusion of the unidirectional perfusion pathway; the tissue status index T includes at least one of the color, surface morphology and compliance of the isolated mouse liver.
[0073] During the enzyme perfusion period when paired samples are obtained, the conductivity detection unit 170 acquires the current outflow volume Q and driving pressure difference ΔP per unit time, with Q and ΔP taken from the same time window. The current conductivity G is calculated based on the outflow volume and driving pressure difference. The relative conductance R is calculated based on the flushing baseline conductance G0 and the current conductance G. G,Right now The baseline flow rate G0 and the current flow rate G use the same time window length, output volume definition, pressure reference, temperature recording, and correction rules. When using pump-controlled flow, the measured output volume is still used to verify the pump setpoint; if the inflow and outflow volumes are continuously unbalanced, leaks, tissue retention, or collection errors are checked first, and the results for that period are not used as liver flow rates.
[0074] When the cannula is re-secured, the cut ends are re-sealed, air bubbles are removed, or the outlet channel is cleared, the original flow trajectory may experience a baseline jump. After correction, first restore the original driving conditions and obtain a stable window; if necessary, establish a post-correction reference value according to pre-verified rules, but do not directly compare the instantaneous value after the anomaly with the original completion interval.
[0075] While obtaining the outflow volume Q and driving pressure difference ΔP, tissue state index T is also obtained, which includes at least one of the following: color, surface morphology and compliance of isolated mouse liver.
[0076] Color indices are obtained under fixed light source, background, camera or observation position, and white balance conditions, and color references are placed in the same image. The pre-defined target area color value or grading card level is used as a component of T, and uncorrected visual colors that vary with ambient light are not used as the sole basis for completion.
[0077] Surface morphology indicators are recorded from a fixed perspective, including liver lobe edges, capsule folds, local bulges, and surface uniformity. When isolated mouse livers show localized bubbles, capsule rupture, abnormal expansion of a single lobe, or only localized softening, these are marked as abnormal morphologies, and the overall appearance is not considered complete even if other areas appear nearly perfect.
[0078] Compliance indicators are recorded using the same contact tool, contact site, loading method, and displacement or load reading rules to minimize variability caused by changes in observation conditions. Testing actions should avoid puncturing the capsule or significantly squeezing out perfusion fluid. When retesting the same liver, a predetermined sequence of locations should be used to avoid deviations caused by repeated measurements at already compressed sites.
[0079] In this embodiment of the application, the establishment of the interval includes a calibration stage and an independent verification stage.
[0080] The calibration phase includes setting multiple stop points within the same applicable stratum to cover under-digestion, suitable candidate endpoints, and over-digestion. Acceptance criteria for cell results are pre-defined based on downstream applications, and R is analyzed in batches that meet these acceptance criteria. E R GThe distribution and time trajectory of T were analyzed, and it was also checked whether batches that did not meet the cell results would fall into the candidate completion interval. When selecting the interval, both missed normal completions and false abnormal completions were considered, and the highest correlation with a single result indicator was not the only goal.
[0081] During the independent review phase, ex vivo liver batches not involved in interval establishment were used. Perfusion was stopped online according to the candidate completed intervals, and the obtained cellular results and any abnormal misjudgments were verified. Only after the review results met the pre-defined acceptance criteria was the interval registered as a version suitable for routine assessment.
[0082] When completing interval registration, the applicable conditions, sample size, data range, judgment expression, number of consecutive satisfactions, retest interval, maximum number of retests, and version effective date should also be registered. If changes occur in mouse source, liver re-stratification, enzyme composition, temperature, driving method, substrate, or instrument settings that could significantly affect the trajectory, bridging verification or recalibration should be performed.
[0083] In this embodiment, when the tissue state index T contains two or more components, each component is stored separately, and colors, shapes, and compliance of different dimensions are not arbitrarily added together. Only when all selected components meet the completion conditions of this determination version, or when the pre-verified combination rules are met, is the tissue state index T recorded as being in the completion interval.
[0084] In this embodiment of the application, R G The completion intervals for T were established through preliminary experiments. During calibration, the corresponding process indicators were correlated with the cell yield, viability, hepatocyte purity, adherence status, or functional indicators after termination. Applicable intervals were determined for each change in mouse age, liver weight, enzyme type, or temperature conditions that were sufficient to affect the endpoint response.
[0085] S06: Based on the enzyme activity penetration ratio R E Relative conductance R G The tissue state index T determines whether to stop the infusion of the enzyme perfusion solution; the relative conductance R G The current flow rate G / flushing baseline flow rate G0.
[0086] Enzyme activity penetration ratio R E Relative conductance R G The tissue status index T is compared with the completion interval calibrated by the pre-experiment to establish three categories of status: completed, continued, and suspected bypass or insufficient contact. It is then determined whether they are all within their respective completion intervals, and thus whether to stop the infusion of enzyme perfusion fluid.
[0087] For details, see attached. Figure 4 As shown, the status determination unit 190 receives R E R GThe algorithm calculates T and determines whether all three (enzyme perfusion fluid, enzyme activity, and enzyme penetration ratio) are within their respective completion intervals. If so, it outputs "digestion complete," stops inputting enzyme perfusion fluid, and proceeds to the termination step. If not, it determines the enzyme activity penetration ratio R. E Is it already in the completion phase, and what is the relative conductance R? G Or the organizational status indicator T does not produce a response consistent with normal completion.
[0088] If the enzyme activity penetration ratio R E It is in the completion interval and has a relative conductance R G If the tissue status indicator T does not produce a response consistent with normal completion, a suspected bypass or insufficient contact status is indicated, and the infusion rate of the enzyme perfusion fluid is paused or reduced. At this time, the following should be checked sequentially: the connection of the inlet vessel segment, the closure of non-target ends, the integrity of the liver capsule, the patency of the outlet channel, and air bubbles in the tubing. Once the abnormality is resolved, the unidirectional perfusion pathway is restored to its original perfusion drive conditions and stabilized, re-fixation, closure, air venting, or clearing treatments are performed to obtain R again. E R G For the remaining uncompleted and unaffected conditions, controlled enzyme perfusion continues. If the abnormality cannot be eliminated or the pressure, flow rate, or liver capsule condition exceeds the preset safety boundary, the enzyme perfusion of the isolated mouse liver is terminated and the batch is marked as pending review or unqualified.
[0089] If the enzyme activity penetration ratio R E Not in the completion interval, and relative conductance R G If the tissue status indicator T shows a response consistent with normal completion, then the enzyme perfusion solution will continue to be infused and samples will be taken again within the specified time. If pressure or flow rate exceeds limits, the membrane is abnormal, or the detection fails during the perfusion process, the enzyme perfusion for that batch will be terminated and the type of abnormality will be recorded.
[0090] If the enzyme activity penetration ratio R E Continuous unresponsiveness, and relative conductance R G If the tissue status indicator T shows a response consistent with normal completion, then check the enzyme activity after infusion, whether the medium change was completed, chelating agent residue, substrate detection, and temperature conditions, rather than simply prolonging the enzyme perfusion.
[0091] When R E R G When T repeatedly enters and exits near the boundary of the completed interval, different T components contradict each other, or a normal trajectory cannot be formed even after correction, the state is marked as uncertain. A limited number of retests are performed on the uncertain state. If the uncertainty is not resolved after reaching the maximum number of retests or the longest enzyme exposure time, the batch is not output as "normally completed" and is treated as a batch awaiting verification or a batch that fails to meet standards.
[0092] Each state transition saves the trigger time, input metrics, validity fields, threshold version used, output status, and operation action, enabling subsequent differentiation between normal completion, invalid detection, suspected bypass, correction recovery, and safe termination.
[0093] S07: After stopping the infusion of the enzyme perfusion solution, add the stop solution, separate and purify to obtain a cell suspension containing primary hepatocytes.
[0094] After stopping the infusion of enzyme perfusion solution, a stop solution containing proteins that reduce or terminate collagenase activity was added to the isolated mouse liver at a temperature lower than that of the enzyme perfusion solution. This allowed the stop solution to reach the intrahepatic pathway and the surface of the liver tissue, thereby terminating the action of collagenase. After separating the liver capsule from the isolated mouse liver in the stop solution, cells were released using low-shear release methods such as gentle shaking, blowing, or tearing to obtain the release solution.
[0095] In this embodiment, low-shear release is initiated under the condition that the liver capsule is easily separable and the isolated mouse liver can be loosened in the stop solution. Using a wide-mouthed container and a tool that does not easily generate high local shear, the capsule and obvious connective tissue are first separated, and then the cells are released in a dispersive rather than compressive manner.
[0096] The released solution is passed sequentially through at least two stages of filtration, with pore sizes decreasing from large to small. The first stage removes trapped membranes, connective tissue, and large tissue fragments, while the second stage intercepts insufficiently dissociated cell clusters. The pore size, material, effective area, maximum batch processing volume, and pre-wetting requirements for both filtration stages are standardized within the same process version. During filtration, excessive pressure is avoided to forcefully compress tissue fragments, thus reducing mechanical shear and debris load. The amount of unpassed tissue or the degree of blockage is recorded before and after filtration.
[0097] The filtered release solution was evaluated for quality based on at least one of the following: cell viability and debris or non-hepatic parenchymal cell load. Cell viability was assessed using a pre-confirmed method capable of distinguishing between intact and inactivated cells; hepatic parenchymal cell purity was assessed using a pre-confirmed method involving morphological counting, cell marker detection, or a combination of both; debris load was assessed using a fixed counting field, particle counting, or other reproducible methods. For each method, the sample size, number of replicates, and calculation formula were recorded.
[0098] Determine whether the quality assessment results meet the preset quality threshold. If they do, perform enrichment at the minimum necessary intensity using either static sedimentation or a single low-speed centrifugation to obtain a purified cell suspension containing primary hepatocytes. The conditions for static sedimentation or a single low-speed centrifugation are selected based on the ability to enrich large volumes of hepatocytes without causing the verified additional viability loss; the actual time, centrifugation force, temperature, acceleration / deceleration settings, and resuspending method are fixed in the process version.
[0099] If the conditions are not met, supplementary purification is performed using differential centrifugation or density media separation, which has been validated through pre-experimentation. The selection of differential centrifugation or density media separation is based on the components to be removed and the cell state. The type, density, osmotic pressure, separation volume, centrifugation conditions, and sampling location of the density media are all validated and recorded before use. After supplementary purification, a quality assessment is performed again to determine whether the quality gate is met. If the acceptance conditions required for downstream use are still not met, the batch is marked as unqualified or restricted for specific uses, and multiple unvalidated rounds of purification are not repeated.
[0100] For cells that meet the quality gate, the cells are resuspended in a culture or preservation system suitable for downstream use, and the total number of cells, number of viable cells, yield per unit liver weight, purity of hepatocytes, resuspension volume, culture or preservation system, adherence status and abnormalities are recorded to obtain a purified cell suspension containing primary hepatocytes.
[0101] The above description is merely a preferred embodiment of this application and is not intended to limit this application. Various modifications and variations can be made to this application by those skilled in the art. Any modifications, equivalent substitutions, improvements, etc., made within the spirit and principles of this application should be included within the protection scope of this application.
Claims
1. A method for the in vitro perfusion separation and purification of primary mouse hepatocytes, characterized in that, include: A unidirectional perfusion pathway was established in isolated mouse livers, wherein the path of the unidirectional perfusion pathway is from the inflow vessel segment through the intrahepatic vascular network to the outflow vessel segment. Flushing fluid is introduced along the unidirectional irrigation path to obtain the flushing baseline conductance G0; Enzyme perfusion solution is introduced along the unidirectional perfusion path, and inlet control sample and outlet sample are obtained before and after the enzyme perfusion solution enters the unidirectional perfusion path, respectively. The influent control sample and the effluent sample were reacted with paired fluorescent quenching peptide substrates under the same detection conditions to obtain the enzyme activity breakthrough ratio R. E ; During enzyme perfusion, the current flow conductance G and tissue status index T of the enzyme perfusion fluid perfusion the unidirectional perfusion pathway are obtained; the tissue status index T includes at least one of the following: color, surface morphology and compliance of isolated mouse liver. According to the enzyme activity penetration ratio R E Relative conductance R G The tissue status index T determines whether to stop the infusion of the enzyme perfusion solution; the relative conductance R G The current flow rate G / flushing baseline flow rate G0; After stopping the infusion of the enzyme perfusion solution, a stop solution was added, and the cells were separated and purified to obtain a cell suspension containing primary hepatocytes.
2. The method for in vitro perfusion separation and purification of primary mouse hepatocytes according to claim 1, characterized in that, The establishment of a unidirectional perfusion pathway in isolated mouse livers includes: The portal vein segment is connected to the output end of the perfusion drive unit in the pathway establishment component, and the vessel fragment located outside the target pathway and not passing through the main intrahepatic vascular network is closed to form a pathway. Inject flushing fluid into the passage to perform low-drive passage acceptance. If the acceptance conditions are met, the passage is a unidirectional perfusion passage.
3. The method for in vitro perfusion separation and purification of primary mouse hepatocytes according to claim 1, characterized in that, The flushing fluid is introduced along the unidirectional irrigation path to obtain the flushing baseline conductance G0, which includes: The flushing fluid is introduced along the unidirectional flow path. Once the flushing fluid is stably introduced, the outflow volume Q0 and the driving pressure difference per unit time are obtained. Based on the liquid output volume Q0 per unit time and the driving pressure difference... The flushing baseline conductance G0 was calculated.
4. The method for in vitro perfusion separation and purification of primary mouse hepatocytes according to claim 1, characterized in that, The enzyme perfusion solution is introduced along the unidirectional perfusion path, and inlet control samples and outlet samples are obtained before and after the enzyme perfusion solution enters the unidirectional perfusion path, respectively, including: Enzyme perfusion solution is introduced along the unidirectional perfusion path. A control sample is taken at the inlet of the unidirectional perfusion path, and the result is determined based on the transport delay. Take a liquid sample from the outlet of the unidirectional irrigation path.
5. The method for in vitro perfusion separation and purification of primary mouse hepatocytes according to claim 1, characterized in that, The enzyme perfusion fluid includes collagenase and neutral protease.
6. The method for in vitro perfusion separation and purification of primary mouse hepatocytes according to claim 1, characterized in that, The same detection conditions include temperature, mixing order, and reading time.
7. The method for in vitro perfusion separation and purification of primary mouse hepatocytes according to claim 1, characterized in that, The fluorescent quenching peptide substrate comprises a peptide segment forming a collagen-like triple helix conformation, with a fluorescent donor group and a quenching group respectively positioned on either side of the bacterial collagenase cleavage site. Before calculating the enzyme activity penetration ratio using the fluorescent quenching peptide substrate, pre-validation is performed using the enzyme preparation used in the enzyme perfusion solution, an enzyme-free control, and at least one non-collagenase proteolytic activity control that may be present in the enzyme preparation. The fluorescent quenching peptide substrate is only used for calculation when the response of the fluorescent quenching peptide substrate to the enzyme preparation is higher than the response to the non-collagenase proteolytic activity control, an initial linear response interval exists in both the influent and effluent matrixes, and the detection results can be output within a preset enzyme perfusion decision window. .
8. The method for in vitro perfusion separation and purification of primary mouse hepatocytes according to claim 1, characterized in that, According to the enzyme activity penetration ratio R E Relative conductance R G The tissue status index T, used to determine whether to stop the infusion of the enzyme perfusion solution, includes: Determine the enzyme activity penetration ratio R E Relative conductance R G Whether the organizational status index T has completed its respective interval; If so, then stop the infusion of the enzyme perfusion solution; If not, then determine the enzyme activity penetration ratio R. E Whether it is already in the completion interval, and the relative flow conductance R G Or the organizational status indicator T does not generate a response consistent with normal completion; If yes, then pause or reduce the input rate of the enzyme perfusion solution, check for deviations and resample; if no, then continue inputting the enzyme perfusion solution within the specified time and resample.
9. The method for in vitro perfusion separation and purification of primary mouse hepatocytes according to claim 1, characterized in that, After stopping the infusion of the enzyme perfusion solution, a stop solution was added, and the cells were separated and purified to obtain primary hepatocytes, including: A stop solution was added to the isolated mouse liver, the liver capsule was separated, and the cells were released to obtain the release solution. The released liquid is filtered in two stages to determine whether it meets the quality threshold. If the conditions are met, allow the cells to settle and then centrifuge to obtain purified primary hepatocytes. If the conditions are not met, use differential centrifugation or density medium separation to supplement the purification process and obtain purified primary hepatocytes.
10. The method for in vitro perfusion separation and purification of primary mouse hepatocytes according to claim 9, characterized in that, The temperature of the terminating solution is lower than that of the enzyme perfusion solution, and the terminating solution contains protein components that reduce or terminate the action of collagenase.
